Pharmacokinetic concepts in brain drug delivery

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 10, Issue , 2014, Pages 127-161

  Hammarlund Udenaes, Margareta ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ATENOLOL; CIMETIDINE; CODEINE; COLCHICINE; DIAZEPAM; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; FENTANYL; FEXOFENADINE; IMIPRAMINE; LOPERAMIDE; MERCAPTOPURINE; METHADONE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; OFLOXACIN; OXYCODONE; PALIPERIDONE; PEFLOXACIN; PHENAZONE; PHENYTOIN; QUINIDINE; RISPERIDONE; RITONAVIR; SUFENTANIL; TERFENADINE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; BRAIN HOMOGENATE METHOD; BRAIN SLICE METHOD; DRUG ABSORPTION; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; INTERSTITIAL FLUID; INTRACELLULAR FLUID; MICRODIALYSIS; NONHUMAN; PHARMACOKINETICS; PHARMACOLOGICAL PROCEDURES; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 85081146394     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-1-4614-9105-7_5     Document Type: Article

References (118)

1. Abbott NJ (2004a) Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int 45:545–552
2. Abbott NJ (2004b) Prediction of blood–brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov Today Technol 1:407–416
3. Abbott NJ, Dolman DE, Patabendige AK (2008) Assays to predict drug permeation across the blood–brain barrier, and distribution to brain. Curr Drug Metab 9:901–910
4. Abraham MH, Chadha HS, Mitchell RC (1995) Hydrogen-bonding. Part 36. Determination of blood brain distribution using octanol-water partition coefficients. Drug Des Discov 13:123–131
5. Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, Elmquist WF (2012) Quantitative Proteomics of Transporter Expression in Brain Capillary Endothelial Cells Isolated from P-gp, BCRP, and P-gp/BCRP Knockout Mice. Drug Metab Dispos 40(6):1164–1169
6. Avdeef A (2011) How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood–brain barrier permeability? Eur J Pharm Sci 43:109–124
7. Avdeef A (2012) Absorption and drug development. Solubility, permeability and charge state. Wiley, New York
8. Avdeef A, Sun N (2011) A new in situ brain perfusion flow correction method for lipophilic drugs based on the pH-dependent Crone-Renkin equation. Pharm Res 28:517–530
9. Bengtsson J, Ederoth P, Ley D, Hansson S, Amer-Wahlin I, Hellstrom-Westas L, Marsal K, Nordstrom CH, Hammarlund-Udenaes M (2009) The influence of age on the distribution of morphine and morphine-3-glucuronide across the blood–brain barrier in sheep. Br J Pharmacol 157:1085–1096
10. Bickel U (2005) How to measure drug transport across the blood–brain barrier. NeuroRx 2:15–26
11. Bostrom E, Hammarlund-Udenaes M, Simonsson US (2008) Blood–brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology 108:495–505
12. Bostrom E, Simonsson US, Hammarlund-Udenaes M (2005) Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. J Pharm Sci 94:1060–1066
13. Bostrom E, Simonsson US, Hammarlund-Udenaes M (2006) In vivo blood–brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/ pharmacodynamics. Drug Metab Dispos 34:1624–1631
14. Bouw MR, Gardmark M, Hammarlund-Udenaes M (2000) Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood–brain barrier as a cause of the antinociceptive effect delay in rats—a microdialysis study. Pharm Res 17:1220–1227
15. Bouw MR, Xie R, Tunblad K, Hammarlund-Udenaes M (2001) Blood–brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats– pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol 134:1796–1804
16. Broccatelli F, Larregieu CA, Cruciani G, Oprea TI, Benet LZ (2012) Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev 64:95–109
17. Chen H, Winiwarter S, Friden M, Antonsson M, Engkvist O (2011) In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms. J Mol Graph Model 29:985–995
18. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood– brain barrier sites. Proc Natl Acad Sci U S A 86:695–698
19. Cserr HF, Cooper DN, Milhorat TH (1977) Flow of cerebral interstitial fluid as indicated by the removal of extracellular markers from rat caudate nucleus. Exp Eye Res 25(Suppl): 461–473
20. Dagenais C, Graff CL, Pollack GM (2004) Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67:269–276
21. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM (2000) Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20:381–386
22. Dai H, Chen Y, Elmquist WF, Yang H, Wang Q, Elmquist WF (2005) Distribution of the novel antifolate pemetrexed to the brain. J Pharm Exp Ther 315:222–229
23. de Lange EC, Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41:691–703
24. Deguchi Y, Yokoyama Y, Sakamoto T, Hayashi H, Naito T, Yamada S, Kimura R (2000) Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood–brain barrier. Life Sci 66:649–662
25. Di L, Artursson P, Avdeef A, Ecker GF, Faller B, Fischer H, Houston JB, Kansy M, Kerns EH, Kramer SD, Lennernas H, Sugano K (2012) Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. Drug Discov Today 17:905–912
26. Di L, Kerns EH, Bezar IF, Petusky SL, Huang Y (2009) Comparison of blood–brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. J Pharm Sci 98:1980–1991
27. Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, Troutman MD, Liston TE (2011) Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos 39:1270–1277
28. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CE, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165–174
29. Doran AC, Osgood SM, Mancuso JY, Shaffer CL (2012) An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug Metab Dispos 40:2162–2173
30. Dubey RK, McAllister CB, Inoue M, Wilkinson GR (1989) Plasma binding and transport of diazepam across the blood–brain barrier. No evidence for in vivo enhanced dissociation. J Clin Invest 84:1155–1159
31. Ederoth P, Tunblad K, Bouw R, Lundberg CJ, Ungerstedt U, Nordstrom CH, Hammarlund-Udenaes M (2004) Blood–brain barrier transport of morphine in patients with severe brain trauma. Br J Clin Pharmacol 57:427–435
32. Fan Y, Unwalla R, Denny RA, Di L, Kerns EH, Diller DJ, Humblet C (2010) Insights for predicting blood–brain barrier penetration of CNS targeted molecules using QSPR approaches. J Chem Inf Model 50:1123–1133
33. Fenstermacher J, Gross P, Sposito N, Acuff V, Pettersen S, Gruber K (1988) Structural and functional variations in capillary systems within the brain. Ann N Y Acad Sci 529:21–30
34. Friden M, Bergstrom F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U (2011) Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39:353–362
35. Friden M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M (2009a) Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos 37:1226–1233
36. Friden M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M (2007) In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35:1711–1719
37. Friden M, Ljungqvist H, Middleton B, Bredberg U, Hammarlund-Udenaes M (2010) Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J Cereb Blood Flow Metab 30:150–161
38. Friden M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M (2009b) Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52:6233–6243
39. Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, Lindmark T, Mabondzo A, Nilsson JE, Raub TJ, Stanimirovic D, Terasaki T, Oberg JO, Osterberg T (2005) In vitro models for the blood–brain barrier. Toxicol in Vitro 19:299–334
40. Gazzin S, Strazielle N, Schmitt C, Fevre-Montange M, Ostrow JD, Tiribelli C, Ghersi-Egea JF (2008) Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood–brain interfaces. J Comp Neurol 510:497–507
41. Golden PL, Pollack GM (1998) Rationale for influx enhancement versus efflux blockade to increase drug exposure to the brain. Biopharm Drug Dispos 19:263–272
42. Gunn RN, Summerfield SG, Salinas CA, Read KD, Guo Q, Searle GE, Parker CA, Jeffrey P, Laruelle M (2012) Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs. J Cereb Blood Flow Metab 32:874–883
43. Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M (2006) Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p, u), and K(p, uu). Drug Metab Dispos 34:318–323
44. Hakkarainen JJ, Jalkanen AJ, Kaariainen TM, Keski-Rahkonen P, Venalainen T, Hokkanen J, Monkkonen J, Suhonen M, Forsberg MM (2010) Comparison of in vitro cell models in predicting in vivo brain entry of drugs. Int J Pharm 402:27–36
45. Hammarlund-Udenaes M (2000) The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev 45:283–294
46. Hammarlund-Udenaes M (2010) Active-site concentrations of chemicals—are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 106:215–220
47. Hammarlund-Udenaes M, Bredberg U, Friden M (2009) Methodologies to assess brain drug delivery in lead optimization. Curr Top Med Chem 9:148–162
48. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A (2008) On the rate and extent of drug delivery to the brain. Pharm Res 25:1737–1750
49. Hammarlund-Udenaes M, Paalzow LK, de Lange EC (1997) Drug equilibration across the blood– brain barrier–pharmacokinetic considerations based on the microdialysis method. Pharm Res 14:128–134
50. Hsiao P, Unadkat JD (2012) P-glycoprotein-based loperamide-cyclosporine drug interaction at the rat blood–brain barrier: prediction from in vitro studies and extrapolation to humans. Mol Pharm 9:629–633
51. Ito K, Uchida Y, Ohtsuki S, Aizawa S, Kawakami H, Katsukura Y, Kamiie J, Terasaki T (2011) Quantitative membrane protein expression at the blood–brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci 100:3939–3950
52. Jeffrey P, Summerfield S (2010) Assessment of the blood–brain barrier in CNS drug discovery. Neurobiol Dis 37:33–37
53. Kaitin KI (2008) Obstacles and opportunities in new drug development. Clin Pharm Ther 83:210–212
54. Kakee A, Terasaki T, Sugiyama Y (1996) Brain efflux index as a novel method of analyzing efflux transport at the blood–brain barrier. J Pharm Exp Ther 277:1550–1559
55. Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327–338
56. Kalvass JC, Maurer TS, Pollack GM (2007a) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: Comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35:660–666
57. Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM (2007b) Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50, u and correlation of in vitro, preclinical, and clinical data. J Pharm Exp Ther 323:346–355
58. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715
59. Kusuhara H, Sugiyama Y (2009) In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24:37–52
60. Lanevskij K, Japertas P, Didziapetris R (2013) Improving the prediction of drug disposition in the brain. Expert Opin Drug Metab Toxicol 9(4):473–486
61. Large CH, Kalinichev M, Lucas A, Carignani C, Bradford A, Garbati N, Sartori I, Austin NE, Ruffo A, Jones DN, Alvaro G, Read KD (2009) The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res 85:96–106
62. Levin VA (1980) Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 23:682–684
63. Lin JH (2008) CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab 9:46–59
64. Liu X, Chen C (2005) Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov Dev 8:505–512
65. Liu X, Chen C, Smith BJ (2008) Progress in brain penetration evaluation in drug discovery and development. J Pharm Exp Ther 325:349–356
66. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J (2005) Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood–brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharm Exp Ther 313:1254–1262
67. Liu X, Tu M, Kelly RS, Chen C, Smith BJ (2004) Development of a computational approach to predict blood–brain barrier permeability. Drug Metab Dispos 32:132–139
68. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M (2009) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787–793
69. Mano Y, Higuchi S, Kamimura H (2002) Investigation of the high partition of YM992, a novel antidepressant, in rat brain—in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB. Biopharm Drug Dispos 23:351–360
70. Maurer TS, Debartolo DB, Tess DA, Scott DO (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175–181
71. Mensch J, Jaroskova L, Sanderson W, Melis A, Mackie C, Verreck G, Brewster ME, Augustijns P (2010a) Application of PAMPA-models to predict BBB permeability including efflux ratio, plasma protein binding and physicochemical parameters. Int J Pharm 395:182–197
72. Mensch J, Melis A, Mackie C, Verreck G, Brewster ME, Augustijns P (2010b) Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability. Eur J Pharm Biopharm 74:495–502
73. Muehlbacher M, Spitzer GM, Liedl KR, Kornhuber J (2011) Qualitative prediction of blood–brain barrier permeability on a large and refined dataset. J Comput Aided Mol Des 25:1095–1106
74. Nicholson C, Phillips JM (1981) Ion diffusion modified by tortuosity and volume fraction in the extracellular microenvironment of the rat cerebellum. J Physiol 321:225–257
75. Nicholson C, Sykova E (1998) Extracellular space structure revealed by diffusion analysis. Trends Neurosci 21:207–215
76. Norinder U, Haeberlein M (2002) Computational approaches to the prediction of the blood–brain distribution. Adv Drug Deliv Rev 54:291–313
77. Norinder U, Sjoberg P, Osterberg T (1998) Theoretical calculation and prediction of brain–blood partitioning of organic solutes using MolSurf parametrization and PLS statistics. J Pharm Sci 87:952–959
78. Ooie T, Terasaki T, Suzuki H, Sugiyama Y (1997) Kinetic evidence for active efflux transport across the blood–brain barrier of quinolone antibiotics. J Pharm Exp Ther 283:293–304
79. Padowski JM, Pollack GM (2011) Influence of time to achieve substrate distribution equilibrium between brain tissue and blood on quantitation of the blood–brain barrier P-glycoprotein effect. Brain Res 1426:1–17
80. Pardridge WM (2004) Log(BB), PS products and in silico models of drug brain penetration [comment]. Drug Discov Today 9:392–393
81. Pardridge WM, Boado RJ, Black KL, Cancilla PA (1992) Blood–brain barrier and new approaches to brain drug delivery. West J Med 156:281–286
82. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 96:3900–3905
83. Reese TS, Karnovsky MJ (1967) Fine structural localization of a blood–brain barrier to exogenous peroxidase. J Cell Biol 34:207–217
84. Reinoso RF, Telfer BA, Rowland M (1997) Tissue water content in rats measured by desiccation. J Pharmacol Toxicol Methods 38:87–92
85. Rosenberg GA, Kyner WT, Estrada E (1980) Bulk flow of brain interstitial fluid under normal and hyperosmolar conditions. Am J Physiol 238:F42–F49
86. Rowland M, Tozer T (2011) Clinical pharmacokinetics and pharmacodynamics. Concepts and applications. Lippincott, Williams & Wilkins, Baltimore and Philadephia
87. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharm Ther 68:231–237
88. Sadiq MW, Borgs A, Okura T, Shimomura K, Kato S, Deguchi Y, Jansson B, Bjorkman S, Terasaki T, Hammarlund-Udenaes M (2011) Diphenhydramine active uptake at the blood–brain barrier and its interaction with oxycodone in vitro and in vivo. J Pharm Sci 100:3912–3923
89. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD (2005) Imaging P-glycoprotein transport activity at the human blood–brain barrier with positron emission tomography. Clin Pharm Ther 77:503–514
90. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517–2524
91. Shen DD, Artru AA, Adkison KK (2004) Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56:1825–1857
92. Shityakov S, Neuhaus W, Dandekar T, Forster C (2013) Analysing molecular polar surface descriptors to predict blood–brain barrier permeation. Int J Comput Biol Drug Des 6:146–156
93. Stevens J, Ploeger BA, Hammarlund-Udenaes M, Osswald G, van der Graaf PH, Danhof M, de Lange EC (2012) Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn 39(5):463–477
94. Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, Stevens AJ, Metcalf AC, Osuna MC, Kilford PJ, Passchier J, Ruffo AD (2008) Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38:1518–1535
95. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P (2007) Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharm Exp Ther 322:205–213
96. Summerfield SG, Stevens AJ, Cutler L, del Carmen Osuna M, Hammond B, Tang SP, Hersey A, Spalding DJ, Jeffrey P (2006) Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharm Exp Ther 316:1282–1290
97. Sun H (2004) A universal molecular descriptor system for prediction of logP, logS, logBB, and absorption. J Chem Inf Comput Sci 44:748–757
98. Sun H, Dai H, Shaik N, Elmquist WF, Bungay PM (2003) Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55:83–105
99. Syvanen S, Hammarlund-Udenaes M (2010) Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs. Current Top Med Chem 10:1799–1809
100. Syvanen S, Xie R, Sahin S, Hammarlund-Udenaes M (2006) Pharmacokinetic consequences of active drug efflux at the blood–brain barrier. Pharm Res 23:705–717
101. Takasato Y, Rapoport SI, Smith QR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247:H484–H493
102. Tamai I, Tsuji A (2000) Transporter-mediated permeation of drugs across the blood–brain barrier. J Pharm Sci 89:1371–1388
103. Tega Y, Akanuma S, Kubo Y, Terasaki T, Hosoya K (2013) Blood-to-brain influx transport of nicotine at the rat blood–brain barrier: involvement of a pyrilamine-sensitive organic cation transport process. Neurochem Int 62:173–181
104. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1989) Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37:159–164
105. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, Moritani S, Tsuruo T, Yamashita J (1992) P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 51:1427–1437
106. Tunblad K, Ederoth P, Gardenfors A, Hammarlund-Udenaes M, Nordstrom CH (2004a) Altered brain exposure of morphine in experimental meningitis studied with microdialysis. Acta Anaesthesiol Scand 48:294–301
107. Tunblad K, Hammarlund-Udenaes M, Jonsson EN (2004b) An integrated model for the analysis of pharmacokinetic data from microdialysis experiments. Pharm Res 21:1698–1707
108. Tunblad K, Hammarlund-Udenaes M, Jonsson EN (2005) Influence of probenecid on the delivery of morphine-6-glucuronide to the brain. Eur J Pharm Sci 24:49–57
109. Tunblad K, Jonsson EN, Hammarlund-Udenaes M (2003) Morphine blood–brain barrier transport is influenced by probenecid co-administration. Pharm Res 20:618–623
110. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T (2011a) Blood–brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther 339:579–588
111. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, Terasaki T (2011b) Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors. J Neurochem 117:333–345
112. Wang Y, Welty DF (1996) The simultaneous estimation of the influx and efflux blood–brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. Pharma Res 13:398–403
113. Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, Read KD (2009) Receptor occupancy and brain free fraction. Drug Metab Dispos 37:753–760
114. Westerhout J, Ploeger B, Smeets J, Danhof M, de Lange EC (2012) Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J 14:543–553
115. Xie R, Bouw MR, Hammarlund-Udenaes M (2000) Modelling of the blood–brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. Br J Pharm 131:1784–1792
116. Xie R, Hammarlund-Udenaes M (1998) Blood–brain barrier equilibration of codeine in rats studied with microdialysis. Pharm Res 15:570–575
117. Young RC, Mitchell RC, Brown TH, Ganellin CR, Griffiths R, Jones M, Rana KK, Saunders D, Smith IR, Sore NE et al (1988) Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J Med Chem 31:656–671
118. Zhao R, Kalvass JC, Pollack GM (2009) Assessment of blood–brain barrier permeability using the in situ mouse brain perfusion technique. Pharm Res 26:1657–1664